Rethink Relievers: Optimize Asthma Therapy with PRN Anti-Inflammatory Relievers
How to participate in the activity: To register for this activity, participants can click the link HERE to request a specific time and date for the academic detailing visit.
Target Audience: Pharmacists
Type of Activity: Knowledge-based
Expiration Date: February 16, 2026
Number of Credit Hours: 0.5 contact hours (0.05 CEUs)
Fee: Free
Learning Objectives:
- Describe the paradigm shift from SABA only to AIR therapies, including supporting evidence
- Description of SMART therapy with evidence, benefits, and dosing recommendations
- Identify the barriers to SMART therapy and methods to address the challenge
- Discuss AIR therapy options beyond SMART therapy
Speaker(s): For a list of potential speakers and disclosures, please visit Academic Detailers/Disclosures
ACPE
The University of Illinois at Chicago Retzky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been assigned an ACPE Universal Activity Number, 0016-0000-24-029-H01-P, which grants 0.5 contact hours (0.05 CEUs) per CE course. Reading the learning objectives and faculty disclosures; participating in the entire knowledge-based activity, active learning activity, post-test, and activity evaluation; estimating the duration of time spent on the activity; and submitting NABP eProfile ID and MMDD are prerequisites for receiving continuing pharmacy education credits. All ACPE credit awarded to participants must be uploaded to CPE Monitor ™ within 30 days of the activity date, pharmacists are required to provide their eProfile ID and date of birth (MMDD) at the time of the activity. Please contact pharmce@uic.edu if you do not see activity information listed within 30 days. For more information and to set up your e-Profile visit: National Association of Boards of Pharmacy – CPE Monitor
Copyright © 2025– The Board of Trustees of the University of Illinois. All rights reserved. Reproduction in whole or in part without permission is prohibited. Privacy Policy